Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will present 20 oral and poster presentations at the 2015 United States & Canadian Academy of Pathology (USCAP) Annual Meeting taking place March 21-27, 2015 in Boston. The company's molecular information products, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer. The data to be presented at USCAP provide further evidence of the clinical utility of Foundation Medicine's comprehensive genomic profiles to complement standard-of-care pathology testing to inform the treatment of cancer patients, support coverage and value-based payment by payers, and aid in the development of targeted therapies. Specifically, the collective data will demonstrate:

  • Patient responses to targeted therapies for a wide range of clinically advanced cancers with poor prognosis, informed by FoundationOne or FoundationOne Heme.
  • Identification of clinically relevant genomic alterations not assayed for as standard of care in rare, aggressive and/or recurrent cancers where targeted therapy can improve outcomes and extend the realm of treatment possibilities.
  • Alternative genomic classifications of certain cancers that may inform targeted treatment decisions where systemic therapy often fails.
  • High concordance between comprehensive genomic profiling and traditional testing modalities, like FISH and IHC. Further, traditional tests have been shown to lack the accuracy and comprehensiveness of comprehensive genomic profiling to identify alterations that, when targeted, have demonstrated benefit to patients.

“We are honored to present at this year’s USCAP annual meeting alongside global leaders in the field of pathology,” said Jeffrey S. Ross, M.D., medical director, Foundation Medicine and chairman of the Department of Pathology at the Albany Medical Center. “The pathology community plays a pivotal role in the diagnosis and future management of both solid tumors and hematologic malignancies. Our team and collaborators look forward to presenting data demonstrating the clinical value of comprehensive genomic profiling and improving clinical outcomes for patients with cancer. Identifying all clinically relevant genomic alterations and potential genomic drivers in relapsed and refractory malignancies is both critically important and extremely challenging.”

As the landscape of known oncogenic drivers and associated targeted therapies across all types of cancers grows, the robust data presented by Foundation Medicine and collaborators at USCAP corroborate how genomic profiling of patients can serve as a major tool for pathologists as they assist medical, surgical and radiation oncologists in the selection of treatment for patients and their enrollment in mechanism-driven clinical trials.

The schedule for oral presentations by Foundation Medicine and/or its collaborators is as follows:

Date & Time: Monday, March 23, 2015 at 8:00 a.m. ET
Title: Comprehensive Genomic Profiling (CGP) of 44 RET-Fused Lung Adenocarcinomas (LADCA) With Histologic and Clinical Correlates
Abstract: 1904
Session: Proffered Papers: SECTION G
Location: CC 311
Presenter: Julia Elvin, M.D., Ph.D., associate medical director & senior pathologist, Foundation Medicine

Date & Time: Monday, March 23, 2015 at 9:15 a.m. ET
Title: BRAF Fusions are Characteristic of Spitzoid Melanomas
Abstract: 473
Session: Proffered Papers: SECTION F
Location: CC 309
Presenter: David Jones, M.D.
Collaborator: Albany Medical College

Date & Time: Monday, March 23, 2015 at 1:15 p.m. ET
Title: Age-Related Genomic Alterations of Histone Modification Genes (HMG) in Non-Hodgkin Lymphoma (NHL)
Abstract: 1523
Session: Proffered Papers: SECTION C
Location: CC Ballroom A
Presenter: Jo-Anne Vergilio, M.D., associate medical director, Foundation Medicine

Date & Time: Tuesday, March 24, 2015 at 8:00 a.m. ET
Title: Reliable Detection of ALK Gene Fusions in Lung Cancers By Hybrid Capture-Based Next-Generation Sequencing: High Concordance with ALK FISH and ALK IHC
Abstract: 1982
Session: Proffered Papers: SECTION F
Location: CC 207
Presenter: Roman Yelensky, Ph.D., senior director, biomarker and companion diagnostic development, Foundation Medicine

Date & Time: Tuesday, March 24, 2015 at 11:15 a.m. ET
Title: Perivascular epithelioid cell tumors (PEComa) Harbor Heterogeneity of Genomic Alterations Within the PI3k/mTOR Pathway as Demonstrated By Comprehensive Genomic Profiling
Abstract: 37
Session: Proffered Papers: SECTION G
Location: CC 208
Presenter: Siraj Ali, M.D., Ph.D., associate director, clinical development and medical affairs, Foundation Medicine

Date & Time: Tuesday, March 24, 2015 at 1:00 p.m. ET
Title: BRAF Gene Fusions Occur Across a Diverse Subset of Human Solid Tumors and Respond to RAF Kinase Inhibitors
Abstract: 1851
Session: Proffered Papers: SECTION H
Location: CC 302
Presenter: Jeffrey S. Ross, M.D., medical director, Foundation Medicine

Date & Time: Tuesday, March 24, 2015 at 1:00 p.m. ET
Title: Comprehensive Genomic Profiling of Brain Glioblastoma Reveals Frequent Clinically Relevant Genomic Alterations
Abstract: 1715
Session: Proffered Papers: SECTION C
Location: CC Ballroom B
Presenter: Zachary Chalmers, research associate, clinical bioinformatics operations, Foundation Medicine

Date & Time: Tuesday, March 24, 2015 at 1:30 p.m. ET
Title: Development of BRAF FISH Assay for the Detection of BRAF Gene Rearrangements Identified in Pancreatic Acinar Cell Carcinomas
Abstract: 1805
Session: Proffered Papers: SECTION F
Location: CC 207
Presenter: Lu Wang, M.D., Ph.D.
Collaborators: Memorial Sloan Kettering Cancer Center, Albany Medical College, Emory University

The schedule for poster presentations by Foundation Medicine and/or its collaborators is as follows:

Date & Time: Monday, March 23, 2015 at 9:30 a.m. ET
Title: Genomic Drivers of Pleural Malignant Mesothelioma Determined by Comprehensive Genomic Profiling: Opportunities for Targeted Therapies
Abstract: 1975
Session: Poster Session I
Poster Board: 288
Locations: CC Exhibit Hall C/D
Presenter: Olga Voronel, M.D.
Collaborator: Albany Medical College

Date & Time: Monday, March 23, 2015 at 9:30 a.m. ET
Title: Comprehensive Genomic Profiling of Bone Chordomas Reveals High Frequency of mTOR Pathway Alterations and Potential New Route to Targeted Therapies
Abstract: 80
Session: Poster Session I
Poster Board: 16
Locations: CC Exhibit Hall C/D
Presenter: Janne Rand, M.D.
Collaborator: Albany Medical College

Date & Time: Monday, March 23, 2015 at 9:30 a.m. ET
Title: Comprehensive Genomic Profiling of Pulmonary Atypical Carcinoid Tumors Reveals Potential New Routes to Targeted Therapies
Abstract: 1915
Session: Poster Session I
Poster Board: 277
Locations: CC Exhibit Hall C/D
Presenter: Albert Huho, MBChB
Collaborator: Albany Medical College

Date & Time: Monday, March 23, 2015 at 9:30 a.m. ET
Title: Comprehensive Genomic Profiling of Esophageal Squamous Cell Carcinoma Reveals a High Frequency and Complex Landscape of Clinically Relevant Genomic Alterations
Abstract: 773
Session: Poster Session I
Poster Board: 117
Locations: CC Exhibit Hall C/D
Presenter: Ashley Tarasen, M.D.
Collaborator: Albany Medical College

Date & Time: Monday, March 23, 2015 at 1:00 p.m. ET
Title: Druggable Genomic Landscape of Advanced Stage Non-Specialized Adenocarcinomas of Salivary Glands
Abstract: 1333
Session: Poster Session II
Poster Board: 168
Locations: CC Exhibit Hall C/D
Presenter: Kai Wang, M.D., Ph.D., senior scientist, Foundation Medicine

Date & Time: Monday, March 23, 2015 at 1:00 p.m. ET
Title: Limited Intratumoral Heterogeneity in Invasive Breast Cancer Genomic Drug Targets
Abstract: 2100
Session: Poster Session II
Poster Board: 268
Locations: CC Exhibit Hall C/D
Presenter: Jeffrey S. Ross, M.D., medical director, Foundation Medicine

Date & Time: Tuesday, March 24, 2015 at 1:00 p.m. ET
Title: Comprehensive Genomic Profiling Reveals a High Frequency of Clinically Relevant Genomic Alteration in Neuroblastoma
Abstract:  1868
Session: Poster Session IV
Poster Board: 292
Locations: CC Exhibit Hall C/D
Presenter: Siraj Ali, M.D., Ph.D., associate director, clinical development and medical affairs, Foundation Medicine

Date & Time: Tuesday, March 24, 2015 at 1:00 p.m. ET
Title: Comprehensive Genomic Profiling (CGP) of 122 Appendiceal Tumors Identifies Genomic Alterations (GA) Associated with Neuroendocrine and Signet Ring Differentiation
Abstract:  623
Session: Poster Session IV
Poster Board: 123
Locations: CC Exhibit Hall C/D
Presenter: Julia Elvin, M.D., Ph.D., associate medical director & senior pathologist, Foundation Medicine

Date & Time: Tuesday, March 24, 2015 at 1:00 p.m. ET
Title: Comprehensive Genomic Profiling of Collecting Duct Carcinoma of the Kidney Reveals a High Frequency of NF2 Genomic Alterations
Abstract: 989
Session: Poster Session IV
Poster Board: 157
Locations: CC Exhibit Hall C/D
Presenter: Norma Palma, Ph.D., senior manager, medical affairs, Foundation Medicine

Date & Time: Wednesday, March 25, 2015 at 9:30 a.m. ET
Title: Comprehensive Genomic Profiling of Papillary Renal Cell Carcinoma Reveals Clinically Relevant Genomic Alterations
Abstract: 808
Session: Poster Session V
Poster Board: 103
Locations: CC Exhibit Hall C/D
Presenter: Siraj Ali, M.D., Ph.D., associate director, clinical development and medical affairs, Foundation Medicine

Date & Time: Wednesday, March 25, 2015 at 1:00 p.m. ET
Title: Comprehensive Genomic Profiling of Extrahepatic Cholangiocarcinoma Reveals a Long Tail of Therapeutic Targets
Abstract: 744
Session: Poster Session VI
Poster Board: 173
Locations: CC Exhibit Hall C/D
Presenter: Jeffrey S. Ross, M.D., medical director, Foundation Medicine

Date & Time: Wednesday, March 25, 2015 at 1:00 p.m. ET
Title: Comprehensive Genomic Profiling (CGP) of Cervical Adenocarcinoma Correlates with the Presence of Absence of High-Risk Human Papillomavirus (HPV) 16 or 18
Abstract: 1129
Session: Poster Session VI
Poster Board: 235
Locations: CC Exhibit Hall C/D
Presenter: Julia Elvin, M.D., Ph.D., associate medical director & senior pathologist, Foundation Medicine

About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of comprehensive genomic profiling, including FoundationOne and FoundationOne Heme, to identify genomic alterations and improve patient outcomes; the clinical relevance of comprehensive genomic profiling in cancer treatment, coverage and payment decisions by payors and the development of targeted therapies; and the potential of genomic profiling to assist pathologists. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that FoundationOne and Foundation Medicine's molecular information platform will not be able to identify genomic alterations in the same manner as prior clinical data, and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2013, which is on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission, may be realized. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.